CareDx Inc is a leading company in the field of precision medicine, specializing in organ transplant diagnostics
The company focuses on improving the lives of transplant patients through innovative testing solutions that help monitor and manage the risk of transplant rejection. By leveraging advanced genomic technologies, CareDx develops and commercializes a range of products, including non-invasive tests that analyze the patient's blood to provide critical information about organ health. Their commitment to enhancing patient care and outcomes has established them as a key player in the transplant community.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor.
Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQCDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 12-15, 2025 in Honolulu, Hawaii.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
TC BioPharm (NASDAQTCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, has partnered with CareDx, Inc. NASDAQ: CDNANASDAQCDNA)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial.
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of healthcare solutions for transplant patients and caregivers, and Dovetail Genomics, a leader in the field of genomic solutions — today announced a strategic partnership to drive the next wave of innovation in HLA genotyping for organ and stem cell transplant matching.
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data and product enhancements being presented at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI). The meeting takes place in Anaheim, California, from October 21-25, 2024.
